Insights

May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF).

A decision in May from the Federal Circuit Court of Appeals has extended the long-standing and well-publicized dispute over inventorship of use of CRISPR-Cas9 technology in eukaryotic cells. When final resolution comes, it will have important implications for users of this technology. Companies currently licensing CRISPR-Cas9 from one of the two groups claiming ownership rights to the fundamental patents covering this technology and those considering licenses or investment in users of the technology should review existing or proposed licenses to better prepare for the potential outcomes of the dispute.